Ms. Eti Mitrany has been serving as SVP Head of Teva’s corporate economic department since 2012, with global responsibility for Teva’s business planning and analysis.
Prior to that Ms. Mitrany held various positions in Teva, including CFO of specialty R&D, and CFO and FP&A of the global branded business.
Ms. Mitrany joined Teva in 1995 as a financial analyst of Copaxone – the first innovative product of Teva for the treatment of multiple sclerosis.
Ms. Mitrany received her BA in Economics and MBA in Finance, both from Tel-Aviv University.
With over 20 years of experience in finance, M&A and business operations, primarily in the pharmaceutical industries, Ms. Mitrany provides broad and experienced knowledge of the global pharmaceutical business and industry.